Imagine a future the place dwelling longer shouldn’t be solely attainable however comes with vitality and well being. As the world grapples with an growing older inhabitants, the race to unlock the secrets and techniques of longevity has grow to be one in all the most dynamic frontiers in science and expertise.
What’s extra covetable than making a living? Probably Living longer
According to the United Nations’ 2022 World Population Prospects report, the variety of individuals aged 60 and above has surpassed 1 billion and will attain 2.1 billion by 2050, accounting for 22% of the world’s inhabitants. This seismic shift introduces huge challenges: elevated charges of persistent ailments, rising healthcare prices, shifts in the labor power, and mounting strain on social safety techniques.
Aging is not a distant scientific idea—it’s a actuality for us all.
In response, longevity is capturing the world’s creativeness—and funding. In 2024 alone, funding in longevity analysis soared to roughly $8.5 billion, a outstanding 220% improve from 2023. Major pharmaceutical firms have taken discover: Roche has dedicated $50 billion to R&D with a major give attention to growing older, whereas Novartis is buying senotherapeutics startups. Across the globe, high-value partnerships are rising, signaling that ageing analysis is transferring from the fringes to the forefront, and quickly changing into a core precedence in the healthcare business.
This international momentum can be mirrored in the Aging Research and Drug Discovery (ARDD) convention. Founded in 2014, ARDD has grown into one in all the world’s most influential gatherings for growing older science, famend as a premier showcase for groundbreaking applied sciences and transformative leads to longevity analysis. Interest continues to rise—underscored by the indisputable fact that this 12 months’s occasion offered out a month prematurely.
Taking place from August 25–29 at the University of Copenhagen, ARDD 2025 will carry collectively an unparalleled roster of expertise: two Nobel laureates, eight of the prime ten consultants in longevity analysis, greater than half of the top-ranked scientists in drugs and well being acknowledged by the Nature Index 2025, and representatives from main analysis establishments. Together, contributors will delve into the newest breakthroughs in areas reminiscent of cell simulation, deep growing older biomarkers, and mobile growing older mechanisms, driving the discipline ever nearer to reaching wholesome longevity for all.
Insilico Medicine: Driving Innovation at the Forefront of Longevity Research
As the founder and one in all the earliest sponsors of ARDD, Insilico Medicine with the mission to increase well being productive longevity has supported the convention for 11 years, persistently presenting cutting-edge, AI-driven analysis on growing older and longevity. In earlier years, the firm has shared vital analysis achievements, together with the novel growing older clock, AI-based growing older biomarker discovery, identification of dual-purpose targets in growing older and illness, and the PreciousGPT series—a transformer-based life mannequin that predicts organic modifications throughout a number of tissues and species from beginning to loss of life.
Insilico has established a long-standing status for analysis and collaboration in the discipline of longevity. In 2016, the firm printed groundbreaking work in Nature Communications on In Silico Pathway Activation Network Decomposition Analysis (iPANDA), a gene expression-based AI technique for biomarker improvement. By 2022, Insilico launched PandaOmics—a goal identification engine that integrates iPANDA with greater than 20 superior AI fashions—enabling the discovery of 145 potential therapeutic dual-purpose growing older targets, with outcomes printed in Aging.
More considerably, Insilico’s dual-purpose goal technique achieved first-in-class proof of idea for AI-driven discovery: Rentosertib (ISM001-055) demonstrated a dose-dependent efficacy trend against idiopathic pulmonary fibrosis (IPF) in a Phase IIa clinical trial. Notably, this investigational drug targets TNIK, a number one age-associated gene linked to a number of hallmarks of growing older.
Insilico’s experience in longevity analysis space additionally has been validated by means of collaborations with esteemed companions worldwide, together with Taisho, Lineage, Juvenescence, and the Buck Institute in goal identification and therapeutic improvement, in addition to Life Extension and SRW in novel dietary supplements.
ARDD 2025: Charting the Future of Healthy Longevity
During ARDD 2025, Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine, will be a part of leaders from Eli Lilly, Biogen, and Fosun Pharma to debate advances in longevity in the pharmaceutical business, scheduled for 17:40–18:40 CET on August 26. He may even ship a devoted discuss on the rational design of geroprotectors and scientific protocols at 19:00–19:20 CET on August 29. Meanwhile, Insilico’s software program and enterprise improvement workforce will likely be actively engaged all through the convention, with senior scientist Fedor Galkin presenting novel goal discovery for IPF and growing older analysis at 19:20–19:40 CET on August 27.
Together, we’re dedicated to tackling the international drawback of growing older head-on with the newest AI applied sciences. We will proceed to deepen human understanding of the organic mechanisms of growing older and take the time to steer humanity one step nearer to “healthy longevity” earlier than translating them into therapies that may really profit humanity.
About Insilico Medicine
Insilico Medicine, a world scientific stage biotechnology firm powered by generative AI, is connecting biology, chemistry, drugs and science analysis utilizing next-generation AI techniques. The firm has developed AI platforms that make the most of deep generative fashions, reinforcement studying, transformers, and different trendy machine studying strategies for novel goal discovery and the technology of novel molecular constructions with desired properties. Insilico Medicine is growing breakthrough options to find and develop modern medicine for most cancers, fibrosis, central nervous system ailments, infectious ailments, autoimmune ailments, and aging-related ailments. www.insilico.com